Supporting undergrads
We seek to positively influence and impact undergraduate students worldwide by bridging the path to rewarding careers that will advance students in STEM2D higher education.
By developing relationships with universities and initiating interactions with students pursuing education in STEM2D fields, we are expanding our reach, programming, and impact on university students across the world. This is accomplished by organizing events and activities with partner universities such as college-to-career programs, panel discussions, guest speakers, innovation challenges, mentoring opportunities, site visits, and more.
By developing relationships with universities and initiating interactions with students pursuing education in STEM2D fields, we are expanding our reach, programming, and impact on university students across the world. This is accomplished by organizing events and activities with partner universities such as college-to-career programs, panel discussions, guest speakers, innovation challenges, mentoring opportunities, site visits, and more.
More from Johnson & Johnson
-
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy. -
Striving for a cure for multiple myeloma: What HCPs need to know
Jordan Schecter, M.D., leader of Johnson & Johnson’s end-to-end development strategy for multiple myeloma, shares insight on the evolving treatment landscape of this rare blood cancer. -
Behind the relentless pursuit of multiple myeloma cures
For 25 years, Johnson & Johnson has pursued innovative blood cancer treatments. Scientist Kodandaram “Ram” Pillarisetti has helped shape that pursuit, from discovering a target that led to an approved bispecific therapy to research exploring a next-generation trispecific antibody approach.
